Fact Sheet
How will a Rebate Model Impact Cash Flow for Price Negotiated Drugs in Medicare Part D?
Dec 18, 2025
Discover how the MFP refund model will affect pharmacy cash flow and rebate timelines for Medicare Part D drugs in 2026, based on IQVIA’s analysis.
- Financing costs for MFP refunds are lower than the pre-MFP baseline, easing pharmacy cash flow.
- 340B rebate payments are processed faster, resulting in even smaller financing costs.
- This may warrant HRSA reevaluating the condition it imposed to demonstrate the performance of the 340B rebate model before it is expanded beyond the 10 drugs in the rebate pilot.
Download the fact sheet to get actionable insights for pharmacy operations and reimbursement planning.
Related solutions
Commercial Solutions
Data, AI, and expertise empower Commercial Solutions to optimize strategy, accelerate market access, and maximize brand performance.
Brand & Marketing
Grow your brand, now and through patent expiry
Market Access
Gain high value access and increase the profitability of your brands